clopidogrel

Latest stories

21d
Business Wire
Cerenis Therapeutics : Résultats du 1er semestre 2016récepteurs P2Y, qui comprend notamment le récepteur P2Y12, cible de médicaments
Cerenis Therapeutics : Résultats du 1er semestre 2016
Business Wire / Posted 21 days ago
récepteurs P2Y, qui comprend notamment le récepteur P2Y12, cible de médicaments à succès tels que l’agent anti-thrombotique Clopidogrel (Plavix®). Les études précliniques ont montré que le CER-209 agit sur la dernière étape de la voie RLT, augmente... Read more
144 related stories
21d
Business Wire
Cerenis Therapeutics: 2016 Half-Year Resultsreceptor family including the P2Y12 receptor which is the target of successful
Cerenis Therapeutics: 2016 Half-Year Results
Business Wire / Posted 21 days ago
receptor family including the P2Y12 receptor which is the target of successful drugs such as the anti-thrombotic agent Clopidogrel (Plavix®). In preclinical studies CER-209 promotes HDL recognition by the liver and increase the activity of... Read more
29d
News-Medical-Net
Study shows non-inferiority of short-term dual antiplatelet therapy in patients with DES placementhad received the Nobori bioabsorbable abluminal-coated stent, with DAPT consist
Study shows non-inferiority of short-term dual antiplatelet therapy in patients with DES placement
News-Medical-Net / Posted 29 days ago
had received the Nobori bioabsorbable abluminal-coated stent, with DAPT consisting of aspirin (81-162 mg/day) combined with clopidogrel (75 mg/day) or ticlopidine (200 mg/day). The study enrolled 3,775 patients with coronary artery disease or acute... Read more

People in this news